COMMENTARY

PMDA Poised to Tap Big Data to Refine Reviews, Safety Steps; Dedicated Center Eyed in 2018

August 12, 2015
The age of big data has arrived for Japanese healthcare regulators. The Pharmaceuticals and Medical Devices Agency (PMDA) has begun taking steps that will enable it to effectively utilize massive amounts of medical information to improve drug reviews and safety…

To read the full story

COMMENTARY

Takeda Pharmaceutical CEO Christophe Weber highlighted the importance of gaining a strong foothold in the world’s largest pharma market at…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…

By Yoshinori Sagehashi

Daiichi Sankyo and GlaxoSmithKline recently announced that they have agreed to dissolve their joint venture company, Japan Vaccine. The failure of this model of joint venture between a major Japanese and foreign drug maker in just six years is disappointing.Over…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…